Tolerance of two cox2 - inhibitors, rofecoxib and celecoxib, in aspirin sensitive asthmatics Source: Eur Respir J 2001; 18: Suppl. 33, 428s Year: 2001
Efficacy and safety of four doses of CHF6001, a novel inhaled phosphodiesterase-4 inhibitor (PDE4i), in patients with moderate-to-severe COPD Source: International Congress 2019 – COPD clinical trials: new molecules and novel insights Year: 2019
Efficacy and safety of BI 671800, an oral CRTH2 antagonist, as add on therapy in poorly controlled asthma patients prescribed an inhaled corticosteroid Source: Annual Congress 2012 - Trials in asthma: asthma exacerbations and severe asthma Year: 2012
Efficacy and safety of BI 671800, an oral CRTH2 antagonist, as add on therapy in poorly controlled asthma patients prescribed an inhaled corticosteroid Source: Annual Congress 2012 - New bronchodilators and other novel drugs for asthma and COPD Year: 2012
Association between cyclooxygenase inhibitor use and efficacy of immunotherapy: a retrospective study Source: Virtual Congress 2020 – Molecular alterations and immunology in lung cancer Year: 2020
The effect of omalizumab on blood eosinophils count in patients with hypersensitivity to non-steroidal anti-inflammatory drugs (NSAID) compare to patients who tolerate NSAID–pilot study Source: International Congress 2018 – Role of IgE and interleukin (IL)-5 in Th2-cell signatures Year: 2018
Roflumilast, a selective phosphodiesterase 4 inhibitor, shows efficacy and safety in the long-term treatment of asthma Source: Eur Respir J 2003; 22: Suppl. 45, 203s Year: 2003
Emerging prognostic biomarkers in non small cell lung cancer patients: Impact of treatment with nimesulide (COX-2 inhibitor) combined with chemotherapy Source: Annual Congress 2011 - Biomarkers and other new methods for lung cancer Year: 2011
Roflumilast, an oral, once-daily PDE4 inhibitor, improves lung function and reduces exacerbation rates in patients with COPD Source: Eur Respir J 2004; 24: Suppl. 48, 21s Year: 2004
Pirfenidone, proton pump inhibitor, N acetyl cysteine (PINPOINT) therapy for IPF: Tolerance and safety profile among Indian patients Source: Annual Congress 2012 - Diffuse parenchymal lung disease III Year: 2012
One-year pulmonary safety and efficacy of inhaled insulin as adjunctive therapy in type 2 diabetes patients poorly controlled on oral agent monotherapy Source: Eur Respir J 2004; 24: Suppl. 48, 618s Year: 2004
Inhalations of ultra-low doses of alkylating drug for the treatment of steroid-dependant asthma: anti-inflammatory effect of therapy Source: Eur Respir J 2001; 18: Suppl. 33, 266s Year: 2001
Can toxicities induced by antituberculosis drugs be better managed in diabetic patients? Source: Eur Respir J, 50 (1) 1700409; 10.1183/13993003.00409-2017 Year: 2017
Comparative analysis of the efficacy of glucocorticosteroids and antimetabolite drugs in treatment of patients with pulmonary sarcoidosis Source: International Congress 2019 – Granulomatous disorders: pathogenesis, epidemiology and clinical issues Year: 2019
Anti-inflammatory effects of add-on atorvastatin therapy during the treatment of COPD patients Source: Annual Congress 2012 - Trials in COPD: novel treatments and insights Year: 2012
Short-course systemic corticosteroids in asthma: striking the balance between efficacy and safety Source: Eur Respir Rev, 29 (155) 190151; 10.1183/16000617.0151-2019 Year: 2020
Roflumilast in coadministration with medications commonly prescribed for COPD: An overview of existing studies Source: Annual Congress 2010 - Pharmacological modulation of biomarkers and management Year: 2010
Adverse effects of second-line drugs during the treatment of multidrug resistant tuberculosis patients Source: Eur Respir J 2005; 26: Suppl. 49, 650s Year: 2005
Oral combination therapy bosentan/sildenafil delays time to clinical worsening in comparison to bosentan monotherapy Source: Annual Congress 2008 - Pulmonary hypertension I Year: 2008
Inhaled corticosteroids: a controversial add-on treatment in COPD Source: Eur Respir J 2010; 36: 973-974 Year: 2010